• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Checklist 3

Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis (Oxlade et al. 2007)
Guideline topic: TB updateQuestion no:1 contacts
Check list completed by Edward Mwarangu
Section 1: ApplicabilityYes/ Partly/ No/ Unclear/ NAComments Partly applicable
  • 1.1 Is the study population appropriate for the guideline?
YesHypothetical model
  • 1.2 Is/are the intervention(s) appropriate for the guideline?
YesTST,
IGRA
Chest X ray
  • 1.3 Is the healthcare system in which the study was conducted sufficiently similar to the current UK NHS context?
NoCanada
  • 1.4 Are costs measured from the NHS and personal social services (PSS) perspective?
No
1.5 Are all direct health effects on individuals included?Partly
  • 1.6 Are both costs and health effects discounted at an annual rate of 3.5%?
No
  • 1.7 Is the value of health effects expressed in terms of quality-adjusted life years (QALYs)?
NoBased on cases detected and persons screened
  • 1.8 Are changes in health-related quality of life (HRQoL) reported directly from patients and/or carers?
No
  • 1.9 Is the valuation of changes in HRQoL (utilities) obtained from a representative sample of the general public?
No
1.10 Overall judgement: Directly applicable/Partially applicable/Not applicable There is no need to use section 2 of the checklist if the study is considered ‘not applicable’.
Not Applicable
Other comments
Markov modelling was used to compare the expected TB cases and costs over 20 years following screening for TB with different strategies among hypothetical cohorts of foreign-born entrants to Canada, or contacts of TB cases. Sequential screening with TST then QFT was more cost effective than QFT alone in all scenarios and more cost-effective than TST alone in selected subgroups.

From: Appendix L, Health economic model - 2011

Cover of Tuberculosis
Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control.
NICE Clinical Guidelines, No. 117.
National Collaborating Centre for Chronic Conditions (UK); Centre for Clinical Practice at NICE (UK).
Copyright © 2006, Royal College of Physicians of London. Updated text, Copyright © 2011, National Institute for Health and Clinical Excellence.

For 2006 original guideline text, no part of the content may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other issue of this publication) without the written permission of the Royal College of Physicians of London. Applications for the Royal College of Physicians of London's written permission to reproduce any part of this publication should be addressed to the publisher.

For 2011 updated text, the material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.